Multiple myeloma (MM) cell line treated with an inhibitor to EZH2/EZH1 (UNC1999), DNA methylation inhibitor (5-azacytidine), and a combination of both.
Multiple myeloma (MM) is a hematopoietic malignancy characterised by the accumulation of neoplastic post-germinal centre, isotype-switched, long-lived plasma cell within the bone marrow. In genetic and clinical terms MM is highly heterogeneous and remains fatal. Here we present the first epigenomic ...
